Home › Breast Cancer › NCT05225428

Video Education With Result Dependent dIsclosure

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Age ≥ 18 years
* Current or prior diagnosis of breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, colorectal cancer, renal cancer, melanoma, or sarcoma
* Ability to understand spoken or written English or Spanish in a healthcare context
* Ability to understand and the willingness to sign a written informed consent document
* Black or Latinx (qualitative assessment study only)

Exclusion Criteria:

* Prior cancer genetic testing
* Prior germline genetic testing
* Active hematologic malignancy (e.g. chronic lymphocytic leukemia)
* Currently pregnant
* Currently incarcerated

About the study

The overall study objective of this trial study is to identify and evaluate strategies to improve the accessibility of the video education with result dependent disclosure (VERDI) model, increasingly utilized as a pre-genetic testing (pretest) education alternative in clinical practice, to better serve a more diverse patient population at risk for hereditary cancers.

What is being tested

• Video Education (behavioral)
• Genetic Counseling (behavioral)

Sponsor: Dana-Farber Cancer Institute · Participants: 1,020 · Started: Aug 4, 2022

Contact the study team

• Huma Q. Rana, MD. MPH · Phone: 617) 632-6292

Official record on ClinicalTrials.gov — NCT05225428

Locations in the U.S.

Conditions

• Breast Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Prostate Cancer
• Colorectal Cancer
• Kidney Cancer
• Melanoma
• Soft Tissue Sarcoma

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.